Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
Cancer Types / Pediatric Cancers / Retinoblastoma / NCI Resources
National Cancer Institute®
Last Modified: February 1, 2002
1
UI - 11697628
AU - Hofmann WK; Tsukasaki K; Takeuchi N; Takeuchi S; Koeffler HP
TI -
Methylation analysis of cell cycle control genes in adult T-cell
leukemia/lymphoma.
SO - Leuk Lymphoma 2001 Sep-Oct;42(5):1107-9
AD - Division of Hematology/Oncology, Cedars-Sinai Research Institute, UCLA
School of Medicine, Los Angeles, California 90048, USA.
Central to many cancers is the aberrant expression of genes that
regulate the cell cycle including the cyclin-dependent kinase inhibitors
known as p15INK4b and p16INK4a, p14ARF and the retinoblastoma (RB)
protein. We performed a detailed analysis of the methylation status of
these genes by methylation specific polymerase chain reaction (MSP) in
tumor cells of 35 adult T-cell leukemia/lymphoma (ATL) patients. We
found in nine of 35 cases (26%) at least one gene methylated. The
frequency of p15INK4b methylation was 7 of 35 (20%). The incidence of
methylation of p14ARF and p16INK4a was two of 35 (6%) and one of 35
(3%), respectively. The RB gene was not found to be methylated in any of
the ATL samples. The data indicate that inactivation of these cell cycle
regulatory genes by hypermethylation is important in the development of
ATL.
2
UI - 11812445
AU - Laquis SJ; Rodriguez-Galindo C; Wilson MW; Fleming JC; Haik BG
TI -
Retinoblastoma in a patient with an X;13 translocation and facial
abnormalities consistent with 13q-syndrome.
SO - Am J Ophthalmol 2002 Feb;133(2):285-7
AD - Department of Ophthalmology, University of Tennessee Health Science
Center, Memphis, Tennessee 38163, USA.
PURPOSE: To report a patient with an X;13 translocation and facial
features of 13q-syndrome who developed retinoblastoma. DESIGN:
Observational case report. METHODS: A 9-month-old girl known to have an
X;13 chromosomal translocation with a break point at 13q12.1 and
dysmorphic facial features characteristic of 13q-syndrome presented with
leukocoria in her right eye. RESULTS: By clinical examination,
retinoblastoma was diagnosed in the right eye. CONCLUSION: Chromosomal
abnormalities on the long arm of chromosome 13 predispose to
retinoblastoma formation and characteristic facial features.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Ms. Sherry discusses how the experience of caring for patients with advanced lung cancer has changed her life. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

